StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
72
This month
3
This week
1
This year
7
Yesterday
1
Publishing Date
2024 - 01 - 26
1
2024 - 01 - 05
1
2023 - 12 - 07
1
2023 - 10 - 20
4
2023 - 10 - 10
1
2023 - 10 - 05
1
2023 - 09 - 22
2
2023 - 08 - 25
2
2023 - 08 - 18
1
2023 - 08 - 07
1
2023 - 07 - 28
1
2023 - 07 - 27
1
2023 - 07 - 19
1
2023 - 06 - 20
1
2023 - 04 - 07
1
2023 - 03 - 27
1
2023 - 03 - 16
1
2023 - 03 - 01
1
2023 - 02 - 28
1
2023 - 02 - 22
1
2023 - 02 - 21
1
2023 - 02 - 16
1
2023 - 01 - 25
2
2022 - 12 - 13
1
2022 - 11 - 22
1
2022 - 10 - 10
1
2022 - 09 - 20
1
2022 - 09 - 12
1
2022 - 08 - 03
2
2022 - 07 - 20
1
2022 - 03 - 17
1
2022 - 03 - 15
1
2022 - 03 - 07
1
2022 - 02 - 14
1
2022 - 01 - 20
1
2022 - 01 - 18
1
2021 - 12 - 27
1
2021 - 12 - 06
1
2021 - 11 - 17
1
2021 - 11 - 11
1
2021 - 10 - 27
1
2021 - 10 - 25
1
2021 - 10 - 01
1
2021 - 09 - 24
1
2021 - 09 - 01
1
2021 - 08 - 25
1
2021 - 08 - 05
1
2021 - 07 - 27
1
2021 - 07 - 22
1
2021 - 07 - 20
1
2021 - 07 - 15
1
2021 - 07 - 12
1
2021 - 06 - 22
1
2021 - 06 - 07
1
2021 - 05 - 13
1
2021 - 04 - 15
1
2021 - 03 - 19
1
2021 - 03 - 16
1
2021 - 03 - 08
1
2021 - 01 - 26
1
Sector
Communications
6
Health technology
72
Manufacturing
1
Tags
Advanced
2
Alliances
2
Antiviral
3
Application
1
Arm
2
Biomarkers
2
Biotech-bay
1
Breast
2
Breast cancer
2
Canada
1
Cancer
29
Candidate
1
Cel
2
Cell
8
Cell carcinoma
2
Clinical trials
1
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
41
Covid
4
Covid-19
1
Disease
4
Drug
1
Enroll
1
Europe
1
Ev-302
1
Fda
2
Hiv
8
Infection
3
Infections
5
Injection
4
Iot
2
Keytruda
30
Lung
8
Lynparza
2
Merck
17
Molnupiravir
5
Ongoing
3
Pharm-country
8
Pharmaceutical
6
Phase 2
5
Phase 2b
4
Phase 3
17
Plus
14
Pneumococcal
2
Positive
3
Program
3
Prostate cancer
5
Renal
2
Research
4
Response
2
Results
6
Risk
6
State
2
Therapy
9
Treatment
8
Trial
45
Trials
8
Update
11
Vaccine
4
Ynote-671
2
Entities
4d molecular therapeutics inc
24
Abb ltd
72
Abbvie inc.
62
Actinium pharmaceuticals, inc.
28
Aldeyra therapeutics, inc.
38
Alnylam pharmaceuticals, inc.
38
Alterity therapeutics limited
26
Altra industrial motion corp.
23
Amgen inc.
25
Anavex life sciences corp.
24
Arcutis biotherapeutics, inc.
29
Arrival
26
Arrowhead pharmaceuticals, inc.
23
Astellas pharma inc
26
Astrazeneca plc
64
Beigene, ltd.
35
Biogen inc.
23
Biovie inc.
28
Bioxcel therapeutics, inc.
26
Bristol-myers squibb company
73
Clearside biomedical, inc.
24
Clene inc
25
Cnh industrial n.v.
69
Cybin inc
26
Cytokinetics, incorporated
29
Dynavax technologies corporation
28
Eli lilly and company
161
Enlivex therapeutics ltd.
25
Exelixis, inc.
28
Fortress biotech, inc.
41
Gates industrial corporation plc
25
Gilead sciences, inc.
48
Global industrial co
38
Honeywell international inc.
53
Horizon therapeutics public limited company
46
I-mab
34
Icon plc
43
Immix biopharma, inc.
26
Immutep limited
34
Incyte corporation
49
Johnson & johnson
203
Medtronic plc
25
Merck & company, inc.
72
Moleculin biotech, inc.
34
Novartis ag
34
Novo nordisk a/s
41
Ocugen, inc.
27
Orange
91
Pds biotechnology corporation
24
Pfizer, inc.
61
Plus therapeutics, inc.
35
Regeneron pharmaceuticals, inc.
44
Regenxbio inc.
29
Sanofi
310
Sellas life sciences group, inc.
24
Sorrento therapeutics, inc.
38
Stag industrial, inc.
32
Takeda pharmaceutical company limited
56
Tg therapeutics, inc.
27
Thermo fisher scientific inc
48
Symbols
ALPMF
1
ALPMY
1
ANIX
1
FNCTF
6
LLY
1
MRK
72
MRNA
1
SGEN
1
Exchanges
Nasdaq
9
Nyse
72
Crawled Date
2024 - 01 - 26
1
2024 - 01 - 05
1
2023 - 12 - 07
1
2023 - 10 - 20
4
2023 - 10 - 10
1
2023 - 10 - 05
1
2023 - 09 - 22
2
2023 - 08 - 25
2
2023 - 08 - 18
1
2023 - 08 - 07
1
2023 - 07 - 28
1
2023 - 07 - 27
1
2023 - 07 - 19
1
2023 - 06 - 20
1
2023 - 04 - 07
1
2023 - 03 - 27
1
2023 - 03 - 17
1
2023 - 03 - 01
1
2023 - 02 - 28
1
2023 - 02 - 22
1
2023 - 02 - 21
1
2023 - 02 - 16
1
2023 - 01 - 25
2
2022 - 12 - 13
1
2022 - 11 - 22
1
2022 - 10 - 10
1
2022 - 09 - 20
1
2022 - 09 - 12
1
2022 - 08 - 03
2
2022 - 07 - 20
1
2022 - 03 - 17
1
2022 - 03 - 15
1
2022 - 03 - 07
1
2022 - 02 - 14
1
2022 - 01 - 20
1
2022 - 01 - 19
1
2021 - 12 - 27
1
2021 - 12 - 06
1
2021 - 11 - 17
1
2021 - 11 - 11
1
2021 - 10 - 27
1
2021 - 10 - 25
1
2021 - 10 - 01
1
2021 - 09 - 24
1
2021 - 09 - 01
1
2021 - 08 - 25
1
2021 - 08 - 05
1
2021 - 07 - 27
1
2021 - 07 - 22
1
2021 - 07 - 20
1
2021 - 07 - 15
1
2021 - 07 - 12
1
2021 - 06 - 22
1
2021 - 06 - 07
1
2021 - 05 - 13
1
2021 - 04 - 15
1
2021 - 03 - 19
1
2021 - 03 - 16
1
2021 - 03 - 08
1
2021 - 01 - 26
1
Crawled Time
00:00
1
01:00
1
11:00
10
12:00
29
12:15
1
12:20
2
12:30
2
13:00
3
13:20
1
13:30
1
14:00
2
14:20
1
14:30
3
15:00
1
16:00
2
18:00
1
19:00
3
19:01
1
20:00
1
22:00
2
23:00
4
Source
www.biospace.com
72
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
entities :
Merck & company, inc.
save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published:
2024-04-19
(Crawled : 13:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
0.33%
|
O:
0.22%
H:
0.37%
C:
0.1%
health
treatment
for
canada
advanced
keytruda
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published:
2024-04-04
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
-3.63%
|
O:
0.24%
H:
0.08%
C:
-2.42%
mk-1084
keytruda
lung
merck
cancer
cell
treatment
trial
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published:
2024-04-03
(Crawled : 13:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
-3.51%
|
O:
0.13%
H:
0.0%
C:
0.0%
cancer
trial
initiated
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published:
2024-03-21
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
1.56%
|
O:
-0.13%
H:
0.4%
C:
-0.06%
ylynk-006
keytruda
lung
merck
update
cancer
cell
trial
plus
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Published:
2024-03-13
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
2.54%
|
O:
0.41%
H:
0.04%
C:
-0.81%
gardasil
vaccine
merck
trials
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
Published:
2024-01-26
(Crawled : 23:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
4.7%
|
O:
0.32%
H:
0.42%
C:
0.26%
keytruda
advanced
therapy
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Published:
2024-01-05
(Crawled : 22:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
7.5%
|
O:
0.08%
H:
0.29%
C:
0.1%
merck
pipeline
trial
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published:
2023-12-07
(Crawled : 18:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
19.08%
|
O:
-0.04%
H:
0.01%
C:
-1.61%
ylynk-008
keytruda
lung
merck
cancer
cell
trial
plus
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
Published:
2023-10-20
(Crawled : 19:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
25.24%
|
O:
-0.44%
H:
3.37%
C:
2.68%
keytruda
cancer
plus
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate
Published:
2023-10-20
(Crawled : 14:30)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
25.24%
|
O:
-0.44%
H:
3.37%
C:
2.68%
keytruda
response
plus
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-10-20
(Crawled : 14:30)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
25.24%
|
O:
-0.44%
H:
3.37%
C:
2.68%
keytruda
lung
cancer
cell
risk
plus
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab
Published:
2023-10-20
(Crawled : 14:30)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
25.24%
|
O:
-0.44%
H:
3.37%
C:
2.68%
keytruda
plus
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-10-10
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
20.36%
|
O:
-0.17%
H:
0.13%
C:
-0.68%
ynote-671
lung
merck
cancer
cell
trial
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
Published:
2023-10-05
(Crawled : 19:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
23.11%
|
O:
0.19%
H:
1.32%
C:
1.21%
keytruda
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Published:
2023-09-22
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
17.85%
|
O:
0.46%
H:
0.0%
C:
-0.82%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
28.47%
|
O:
-2.93%
H:
1.22%
C:
0.32%
keytruda
lung
merck
update
cancer
cell
trials
plus
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Published:
2023-09-22
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
17.85%
|
O:
0.46%
H:
0.0%
C:
-0.82%
ev-302
merck
cancer
trial
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Published:
2023-08-25
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
14.92%
|
O:
0.45%
H:
0.35%
C:
0.25%
mk-0616
candidate
merck
program
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Published:
2023-08-25
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
14.92%
|
O:
0.45%
H:
0.35%
C:
0.25%
leap-010
keytruda
merck
update
cell
trial
plus
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Published:
2023-08-18
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
15.48%
|
O:
0.05%
H:
0.49%
C:
0.21%
spark-005
welireg
renal
merck
cell
trial
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
Published:
2023-08-07
(Crawled : 14:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
19.79%
|
O:
0.28%
H:
0.94%
C:
0.76%
ANIX
|
$3.12
0.65%
0.64%
33K
|
Health Technology
|
-16.8%
|
O:
0.0%
H:
2.66%
C:
-4.27%
keytruda
arm
vaccine
breast
cancer
ongoing
trial
← Previous
1
2
3
4
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.